# Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

> **NCT06993610** · PHASE2 · RECRUITING · sponsor: **Zura Bio Inc** · enrollment: 225 (estimated)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **BIOLOGICAL:** Tibulizumab Dose A
- **BIOLOGICAL:** Tibulizumab Dose B
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06993610
- **Lead sponsor:** Zura Bio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06993610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06993610, "Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06993610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*